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Abstract 
Background and main text: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex and 
controversial clinical condition without having established causative factors. Increasing numbers of cases during 
past decade have created awareness among patients as well as healthcare professionals. Chronic viral infection as a 
cause of ME/CFS has long been debated. However, lack of large studies involving well‑designed patient groups and 
validated experimental set ups have hindered our knowledge about this disease. Moreover, recent developments 
regarding molecular mechanism of pathogenesis of various infectious agents cast doubts over validity of several of 
the past studies.
Conclusions: This review aims to compile all the studies done so far to investigate various viral agents that could be 
associated with ME/CFS. Furthermore, we suggest strategies to better design future studies on the role of viral infec‑
tions in ME/CFS.
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Background
Myalgic encephalomyelitis/chronic fatigue syndrome 
(ME/CFS) is a disease that causes central nervous sys-
tem (CNS) and immune system disturbances, cell energy 
metabolisms and ion transport dysfunction, as well as 
cardiovascular problems, gastrointestinal dysfunction, 
cognitive impairment, myalgia, arthralgia, orthostatic 
intolerance, inflammation and innate immunity dis-
turbances. The main clinical sign is persisting chronic 
fatigue, which is not relieved by rest and lasts for more 
than 6  months [1]. A large group of patients remains 
wheelchair-dependent and many remain housebound or 
even bedbound [2].
ME/CFS is sporadic with occasional outbreaks [3]. 
Currently around 80% of ME/CFS cases are undiagnosed 
[4]. According to the available literature, already back in 
2009 around 17 million people were diagnosed with this 
disease, including 800,000 patients in the United States 
of America and 240,000 in the United Kingdom [5]. Eti-
ological factors for ME/CFS include genetic predisposi-
tion, stress, trauma, exposure to toxins, physical activity 
and rest ratio, as well as a recent history of infectious 
disease [2]. Females within the age group of 30–39 years 
are more prone to this disease [6]. Nevertheless, ME/CFS 
can affect individuals from all races, genders, age groups 
and social statuses. Population studies show that the 
prevalence of ME/CFS worldwide is from 0.2% of clini-
cally diagnosed up to 3.48% of self-reported population 
depending on the applied diagnostic criteria. Most of 
the patients with ME/CFS suffer from long lasting symp-
toms, with only 6% of patients experiencing remission of 
the disease [7–9]. ME/CFS symptoms range from long 
lasting fatigue, memory loss, difficulty concentrating, 




*Correspondence:  bhupesh.prusty@uni‑wuerzburg.de 
3 Institute for Virology and Immunobiology, Würzburg, Germany
Full list of author information is available at the end of the article
Page 2 of 25Rasa et al. J Transl Med  (2018) 16:268 
and un-refreshing sleep to extreme fatigue after exertion. 
The pathomechanisms of ME/CFS are still unknown, and 
there are no standardized biological markers or tests for 
diagnostics; therefore, even the existence of this medical 
diagnosis has been questioned for long time [10].
During the past 2  decades, few illnesses have been as 
extensively discussed as chronic fatigue syndrome (CFS). 
A consensus for the proper diagnostic definition for CFS 
was reached in 1994 on a case definition from the United 
States Centers for Disease Control and Prevention [11]. 
Therefore, prolonged fatigue is defined as self-reported, 
persistent fatigue lasting 1  month whereas chronic 
fatigue is persistent or relapsing fatigue lasting 6 months 
or longer [11]. Later in 2011 International Consensus 
Panel (ICP) developed International Consensus Criteria 
suggesting that this disease is to be defined as myalgic 
encephalomyelitis (ME) due to neuropathological inflam-
mation [12].
Clinical evaluation for identifying underlying or con-
tributing conditions of chronic fatigue is required before 
further diagnosis or classifications can be made. Besides 
persistent post-exertional fatigue, ME/CFS is charac-
terized by substantial symptoms related to cognitive, 
immune and autonomous dysfunctions [13, 14]. Though 
ME/CFS is a chronic illness of uncertain cause with 
unknown pathogenesis, there is abundant evidence of an 
underlying biological process. Since sudden disease out-
breaks in patients start with a “flu-like” illness, it seems 
plausible that an infectious agent can trigger the syn-
drome. In fact, viral-like illnesses appear to precede ME/
CFS onset in approximately 50% of patients [15]. In addi-
tion, there are indications that immunological dysfunc-
tion may contribute to the emergence of symptoms [16].
The pathogenesis of ME/CFS is likely multi-factorial 
and various microbial and viral infections are consid-
ered to be the possible trigger factors of ME/CFS. The ill-
ness has been frequently accompanied with various viral 
infections and studies have been conducted on associa-
tion of ME/CFS with Epstein–Barr virus (EBV) [17, 18], 
cytomegalovirus (CMV) [19], human herpesvirus (HHV) 
6, HHV-7, HHV-8 [20–22], human parvovirus B19 
(B19V), enteroviruses [23], lentivirus [24] and bacteria as 
mycoplasma [25], Lyme disease causing borrelia, Q fever 
causing Coxiella burnetii [26] and other pathogens.
Still, the association of ME/CFS with a single infec-
tious agent has not been confirmed, and the role of viral 
infections in ME/CFS remains obscure [2, 27]. This may 
be attributed to the small size and/or heterogeneity of 
studied ME/CFS populations, not well-characterized 
ME/CFS patients, lack of adequate controls, high preva-
lence of persistent viral infection in the general popula-
tion, different methodological approaches applied and so 
on. Here we present an overview of studies addressing 
the possible association of viral infections with ME/CFS, 
focusing on human herpesviruses, B19V, and enterovi-
ruses, which all can trigger ME/CFS. These viruses, after 
an acute infection, remain in the body as mostly latent, 
persistent infections and may reactivate under various 
conditions. Immunologic disturbance associated with 
ME/CFS may be the result of viral infection or may lead 
to reactivation of latent viruses. Once reactivated, the 
viruses may contribute to the morbidity of ME/CFS via 
inflammation and immune dysregulation, especially the 
herpesviruses EBV and HHV-6, which infect immune 
cells [28]. Viral infections can trigger an autoimmune 
response as well [29]. In the majority of ME/CFS cases, 
there is no conclusive evidence for chronic viral infec-
tion, but it is plausible that viruses could act via a “hit and 
run” mechanism; this theory proposes that viruses trigger 
the disease, cause immune abnormalities and leave a dys-
functional immune system and/or autoimmunity.
Human herpesviruses
According to the International Committee on Taxonomy 
of Viruses, Herpesviridae family includes Alphaherpes-
virinae, Betaherpesvirinae and Gammaherpesvirinae 
subfamilies. Currently there are nine human herpesvi-
ruses: herpes simplex virus (HSV)-1, HSV-2, varicella 
zoster virus (VZV), EBV, CMV, HHV-6A, HHV-6B, 
HHV-7, HHV-8. HHV-6 and HHV-7, members of the 
Herpesviridae family, Beta-herpesvirinae subfamily, 
Roseolovirus genus, are most studied human pathogens 
in association with ME/CFS [30]. HHV-6A was first iso-
lated in 1986 from peripheral blood mononuclear cells 
(PBMCs) of patients with acquired immunodeficiency 
syndrome (AIDS) and lympholeukosis [31]. HHV-7 was 
first isolated in 1990 from  CD4+ lymphocytes of healthy 
adult [32]. Primary infection with these viruses usually 
is observed in early childhood—from age of 6 months to 
3 years. They can cause Roseola infantum or Exanthema 
subitum with fever, rashes and elevated body temperature 
lasting for 3 to 5  days. In addition, it can affect several 
organ systems, including CNS [33]. Likewise, infection 
course can be asymptomatic [34]. HHV-6B and HHV-7 
are widespread and prevalence is more than 90% of gen-
eral population [35]. The seroprevalence of HHV-6A is 
unknown. However one study of Chinese individuals 
put the prevalence at 11% of controls [36]. One feature 
of all herpesviruses is that they can establish a lifelong 
persistent infection termed latency [37]. Latent HHV-6 
can reside in a dormant state inside human host cells 
by integrating viral genome into telomeric ends of host 
cell chromosomes (ciHHV-6) [38]. Recently also chro-
mosomal integration of HHV-7 into the host genome 
was discovered [39]. During latency, minimal viral tran-
scription and no production of infectious virions occurs, 
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resulting in no detectable clinical complications. How-
ever, activated forms of HHV-6A/B and HHV-7 are 
known to have immunomodulating properties such 
as modulating the expression of several cytokines and 
chemokines or inducing immunosuppression by trigger-
ing apoptosis in lymphocytes [40–42]. Since both viruses 
are ubiquitous, concurrent infection is common and it 
has also been reported, that HHV-7 can reactivate HHV-
6A/B [43–45].
Reactivation of latent HHV-6A/B can be caused by 
various stress conditions leading to increased severities 
of multiple human disorders [46, 47]. Even though evi-
dence is lacking, it is also possible that exposure to cer-
tain drugs could reactive ciHHV-6. One known chemical 
to reactivate HHV-6 in vitro is the HDAC inhibitor Tri-
chostatin A [48]. Similarly two other commonly known 
pharmaceuticals, sodium valporate and amoxicillin, also 
enhance HHV-6 replication [49, 50]. Virus reactivation 
is possible in cases of immune disturbances, long-term 
stress, immunosuppressive therapy, prolonged anaesthe-
sia, transplantation, AIDS and others [21]. For example, 
HHV-6A reactivation has been found in patients with 
multiple sclerosis (MS) [51] and HIV infection [52] and 
HHV-6B reactivation has occurred in amnesia [53] and 
hepatitis [54]. The virus can also reactivate in the pres-
ence of malignant and non-malignant diseases [55] and 
HHV-6A antibodies are a risk factor for non-Hodgkin 
lymphoma [36].
Due to its life-long persistence and its broad tissue 
tropism, HHV-6 has been speculated to be a possible 
trigger for ME/CFS. The involvement of herpesviruses 
in ME/CFS was already considered in 1988, when sero-
logical evidence pointed to reactivation of HHV-6 among 
patients, and a subset of patients were found to exhibit 
higher levels of antibodies against the EBV viral capsid 
antigen (VCA) and early antigen (EA) but an absence of 
antibodies to EBNA [56]. Based on earlier reports and 
presentations, Ablashi suggested in 1994 that ME/CFS 
could be a result of immunological disturbances after 
herpesvirus reactivation [57]. Investigating this hypothe-
sis, Buchwald et al. started the first large study [20], when 
the case definition for ME/CFS had not yet been made. 
Their study included 259 patients with ME/CFS symp-
toms. Serum chemistry tests and polymerase chain reac-
tion (PCR) assays confirmed the finding of active HHV-6 
infection in 70% of patients. Even though they suggested 
that active replication of HHV-6 represented reactivation 
of latent infection due to immunologic dysfunction, they 
did not directly address HHV-6 playing a role in produc-
ing ME/CFS symptoms.
Follow-up studies using only serological techniques 
could not differentiate between active and latent infec-
tion [21, 22] but revealed a slight tendency to an 
association between ME/CFS and HHV-6, with a greater 
prevalence and higher levels of HHV-6-specific anti-
bodies in patients, as well as a greater prevalence of 
DNA in PBMCs from those with ME/CFS. Notably, in 
both of these studies, HHV-6A was found to predomi-
nate among ME/CFS patients. Moreover, an associa-
tion between active HHV-6 infection and ME/CFS has 
been demonstrated in studies distinguishing between 
active and latent infection using immunofluorescence 
assays directed against HHV-6A antigens or early anti-
body assays [58, 59]. On the other hand, there are several 
studies in which both serological techniques as well as 
PCR-based techniques distinguishing between active and 
latent infection lead to the conclusion that HHV-6 infec-
tion does not correlate with ME/CFS [60, 61]. Chapenko 
et al. [62] also evaluated whether HHV-6 infections could 
be the causative agent for ME/CFS. They found active 
HHV-6 more often in ME/CFS patients than controls, 
and active infection correlated with the occurrence of the 
clinical symptoms of ME/CFS, including lymphadenopa-
thy, subfebrility, and malaise after exertion.
The presence of HHV-7 and other HHVs has been 
determined in patients with ME/CFS. Sairenji et  al. 
revealed 100% HHV-7 seropositivity among 20 patients 
[63]. In another study involving 17 ME/CFS patients, 
HHV-7 reactivation was detected more frequently than 
HHV-6 reactivation and concurrent active HHV-6 and 
HHV-7 infection was accompanied by immunological 
changes in the form of significantly increased  CD95+ 
cells, decreased  CD3+ and  CD4+ T cells, and a lower 
CD4/CD8 ratio [64]. Active HHV-6, HHV-7 and B19V 
infection/co-infection was confirmed analysing 108 
patients with ME/CFS [62].
However, PCR analysis showed a similarly high detec-
tion rate of HHV-7 genomic sequences among patients 
with ME/CFS and controls (82% vs 83%) [65]. In another 
study, the percentage of HHV-6, HHV-7 and co-infection 
was similar between patients and controls; nevertheless, 
HHV-7 was approximately two times more prevalent 
than HHV-6, with HHV-6 and HHV-7 DNA detected 
in the PBMCs of 26.7% and 69.9% of healthy adults, 
respectively, and 35.1% and 77.3% of ME/CFS patients 
[66]. Others found HHV-7 DNA in only 7.7% of periph-
eral blood lymphocyte samples from patients with ME/
CFS using PCR [67]. In addition, detection of HHV-7 
in a high percentage of gastro-intestinal biopsies from 
patients (85–92%) and controls (66–83%) with quanti-
tative PCR (qPCR) is reported, though without statisti-
cal difference between the groups [68]. No difference 
between severity of symptoms and viral load of HHV-6 
and HHV-7 in saliva and PBMC of ME/CFS patients and 
controls was shown [69]. Besides, detectable reactivation 
of HHV-6A/6B and HHV-7 in saliva is considered as a 
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biomarker for physiological fatigue, and can therefore be 
used to distinguish between pathological and physiologi-
cal fatigue [70].
There is no statistically significant difference between 
reported studies that have found no correlation between 
HHV-6/HHV-7 infection/co-infection and ME/CFS (in 
total 17) and publications that noted a correlation (in 
total 12) (P = 0.2935) (Table 1). Nevertheless, some study 
cohorts are rather small to draw general conclusions 
about the association of a viral infection with the disease.
Several groups have also reported co-infections of EBV 
with HHV-6 in ME/CFS patients [63]. Serological analy-
sis has revealed a higher frequency of antibodies to EBV 
VCA in patients than controls. In addition, these serum 
antibodies could persist for several years, indicating that 
immune disturbances may allow viral reactivation [71]. 
An abnormal immune response to EBV infection has 
been reported in ME/CFS cases; however, later publica-
tion showed no differences of EBV prevalence among 
patients and controls [72, 73]. Although Manian and col-
leagues found higher titers of IgG class antibodies against 
EBV viral capsid antigen in patients than in controls, they 
did not find a statistically significant difference in titers of 
antibodies to early antigens of EBV, HSV-1, HSV-2 and 
HHV-6 in patients compared to healthy controls. There-
fore, they did not conclude that there was a significant 
association between these infections and ME/CFS [74]. 
Elsewhere, ME/CFS patients’ EBV antibody titers were 
not significantly different compared to controls [75]. In 
1991, Landay et al. found antibodies to EBV early antigen 
significantly more frequently among ME/CFS patients 
than healthy adults, but they observed equal rates of EBV 
VCA and EBNA seropositivity among patients and con-
trols [76]. At the same time, other studies showed no cor-
relation between EBV infection, nor CMV infection, and 
ME/CFS [77, 78]. A very low percentage of EBV-specific 
IgG class antibodies in patients and controls has been 
described [79]. Zhang et  al. have shown that EBV sero-
prevalence (VCA IgG) among ME/CFS patients was sim-
ilar to that of the general population, but VCA IgM titers, 
EBNA IgG titers, and EBV-related genes were associated 
with ME/CFS subtypes [80]. Moreover, in this cohort, 
most ME/CFS patients demonstrated primary infec-
tion/reactivation serostatus, while the serostatus of con-
trols most often corresponded to the late phase of EBV 
infection.
In some reports, EBV was not detected in blood 
plasma by PCR [61], and no difference was revealed in 
the frequency of EBV genomic sequences detected in 
stomach and duodenum biopsies by qPCR [68]. Like-
wise, other studies using immunofluorescence, enzyme-
linked immunosorbent assay (ELISA), PCR and western 
blot have shown that EBV is present, though not sig-
nificantly more often in patients with ME/CFS than in 
controls [81–84].
Recently published data also support the hypothesis 
on herpesviruses involvement in ME/CFS development 
due to expression of antibodies against herpesviruses-
encoded deoxyuridine triphosphate nucleotidohy-
drolases (dUTPases) that activates humoral immune 
response [85]; anti-EBV and HHV-6 dUTPase anti-
bodies were present in 55.4% and 54.06% of ME/CFS 
patients in one cohort, respectively. The same study 
found EBV dUTPase antibodies in 29.09% of patients 
and 25.83% of controls overall from a separate cohort. 
Compared to controls, the patients had significantly 
higher anti-EBV dUTPase antibodies.
Serum antibody and genomic sequence analysis of 
HSV, VZV, EBV, CMV, HHV-6, HHV-7, HHV-8, JC 
virus, BK virus, and B19V in 22 monozygotic twin pairs, 
of which one twin met criteria for ME/CFS and the 
other twin was healthy, revealed no differences between 
the group of twins with ME/CFS and the healthy twins 
[61]. Similarly, Cameron and co-workers did not find 
significant differences in EBV, HHV-6, nor CMV sero-
positivity and viral loads between 20 ME/CFS patients 
and 10 controls using qPCR as well as serological assays 
for HHV-6 IgG, CMV IgM, and EBV IgG VCA p18, IgG 
EBNA-1, and IgG EA [83]. Landay et  al. also failed to 
find any serological links between these viruses as well 
as adenovirus, HTLV I/II, HIV, papovavirus, human 
spumavirus, rubeola, and coxsackie B4 and the patho-
genesis of ME/CFS [76] Elevated IgG titers to CMV 
were demonstrated in only 6/107 (6%) patients with 
ME/CFS and only rarely were HSV, coxsackievirus, 
chlamydia, campylobacter, yersinia or candida infec-
tions observed [81]. Likewise, serum analysis revealed 
no correlation between ME/CFS and CMV, HSV-1, 
HSV-2 and adenovirus in another report [20]. However, 
analysis of more ME/CFS patients and controls showed 
the presence of CMV IgM p52 and CM2 antibodies in 
16/34 patients and none of the controls, suggesting an 
etiologic role of CMV in ME/CFS [86]. HHV-8, which 
has been infrequently studied in this disease, was found 
in 2/35 (5.7%) ME/CFS patients and in 1/25 (4%) con-
trols [22].
Although an association of ME/CFS with viral infec-
tions has not been demonstrated in all studies, ME/
CFS can be triggered by various factors, and infections 
could contribute to a subgroup of ME/CFS patients [66, 
83]. Moreover, autoimmune, immune, metabolic and 
psychological disturbances could emerge due to infec-
tious disease [2].
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Enteroviruses
Single-stranded positive-sense RNA viruses from the 
Enterovirus genus belong to the Picornaviridae fam-
ily. They comprise a large group of more than 70 differ-
ent enteroviruses that have the ability to infect humans. 
Although enteroviral infections in humans are frequently 
asymptomatic, they can exert a variety of symptoms 
during acute infections. In addition, chronic enteroviral 
infections have been implicated in myocarditis [87–89] 
and in juvenile-onset type-1 diabetes [90].
The role of enterovirus infection as a potential factor 
in the etiology of ME/CFS has been suspected for about 
3 decades. At the same time, it has been largely disputed, 
as the data from the literature are controversial. RNA 
of enteroviruses has been found in variety of specimens 
(blood, stool, gastric and muscle biopsy) from ME/CFS 
patients more frequently compared to control subjects 
(Table  2). Clements et  al. detected enterovirus-specific 
sequences in 36/88 (41%) serum samples from chronic 
fatigue patients, 22/82 (27%) acutely ill individuals, and 
3/126 (2.4%) healthy individuals [91]. In further analysis, 
the same group determined the prevalence of enterovi-
rus DNA and neutralising antibody in ME/CFS patients. 
Whereas enteroviral sequences in serum were found by 
PCR more frequently in the ME/CFS group (42%) than 
in the control group (9%), there were no statistical differ-
ences regarding coxsackievirus B antibodies in the neu-
tralisation tests (positive: ME/CFS 34%, controls: 41%) 
[92].
Gow et  al. reported on the detection of enteroviral 
RNA in muscle biopsies from 53% of 60 ME/CFS in 
comparison to 15% of 41 controls [93]. Furthermore, 
quadriceps muscle biopsy samples from 20.8% of the 48 
ME/CFS patients were found to be positive for entero-
virus  sequences by reverse transcription (RT)-PCR, 
while all 29 control samples were negative [94]. In a 
study by Bowles et  al. [95], molecular hybridization 
detected enteroviral RNA in muscle biopsies from 41 
of 148 patients with ME/CFS, 25 of 96 patients with 
inflammatory muscle disease, and only two of 152 con-
trols. In an earlier study, the same group had postulated 
that the enteroviral persistence in the muscle might be 
caused by a defect in the control of viral RNA synthesis 
as they found approximately equal amounts of entero-
viral positive and negative RNA strands, in contrast to 
lytic infections, in which positive RNA strands domi-
nate [96]. They speculated that persistence of viral RNA 
without synthesis of viruses could contribute to mus-
cle dysfunction. In 2003, detection of enteroviral RNA 
without production of viral proteins was reported by 
Douche-Aourik et al., whose analysis of muscle biopsy 
samples revealed virus RNA positive samples in 13% 
(4/30) of ME/CFS patients and none of the controls 
[97]. Enteroviral VP-1 protein could not be stained by 
immunohistochemistry in any of the samples.
In 2008, Chia et al. found that 135/165 (82%) antrum 
biopsy specimens stained positive for enterovirus VP1 
within parietal cells, whereas significantly fewer con-
trols were stained positive (7/34, 20%) [98]. Enterovi-
rus RNA was detected in 9/24 (37%) paraffin embedded 
biopsy samples, and only 1/21 controls had detectable 
enterovirus RNA. One out of 3 patients had detectable 
enterovirus RNA from two follow-up samples taken 
4 years apart, whereas 5 patient samples showed tran-
sient growth of non-cytopathic enteroviruses [98]. In 
another study from the same group, 3 patients with 
acute enteroviral infection developed symptoms of 
ME/CFS during follow-up. Enteroviral persistence 
was demonstrated by detection of enteroviral RNA 
sequences in gastric biopsy specimens and in periph-
eral blood leukocytes (PBL) by qualitative RT-PCR [99]. 
It was also shown by Galbraith et al. that enteroviruses, 
19/20 of which were substantially different from previ-
ously described enteroviruses, can establish persistent 
infection, and in some cases, they can lead to the mani-
festation of ME/CFS [100]. In the group of patients who 
had been referred for assessment of fatigue, 44/238 
serum samples and 29/175 throat swab samples were 
positive by enteroviral PCR assay, while sera from 3/130 
healthy individuals were positive using the enteroviral 
PCR assay [100]. In a following study, eight individuals 
with ME/CFS were positive for enteroviral sequences, 
which were detected by PCR in two serum samples 
taken at least 5  months apart [101]. In addition, sero-
logical evidence has indicated that enteroviral activity 
may contribute to ME/CFS; increased titers of antibod-
ies against coxsackieviruses B1 and B4 have been found 
among patients [74], and in a separate group, entero-
virus IgG class antibodies were present in 49% of ME/
CFS patients. Within this cohort, acute infections were 
observed in 5% of patients [80]. The results of antivi-
ral treatment provided additional arguments in support 
of a potential role for enteroviruses in the pathogenesis 
of ME/CFS, as 7 out of 10 ME/CFS patients with per-
sistent enterovirus infection were successfully treated 
with alpha interferon and ribavirin or a combination of 
alpha and gamma interferon [102].
A study focussing on the analysis of immune activa-
tion in ME/CFS found a significantly higher prevalence 
of coxsackievirus infection in 63 ME/CFS patients (90%) 
in comparison to 40 controls (65%). However, geomet-
ric mean antibody IgG titers were similar in both groups 
[76]. In contrast, another study found elevated IgG-
titers against coxsackievirus in only 6% of 107 ME/CFS 
patients, arguing against a major role of active coxsacki-
evirus infection in ME/CFS, at least in that cohort.
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Other studies were not able to detect enterovirus 
infection in ME/CFS patients’ blood, stool, serum, cer-
ebrospinal fluid (CSF) and muscle biopsy samples [76, 
81, 103–105]. In addition, there were no significant dif-
ferences in the rates of detection of enteroviral RNA in 
muscle biopsies from a group of patients with  ME/CFS 
(26.4%), compared with a group of patients with other 
neuromuscular disorders (19.8%). It was concluded that 
persistent enterovirus infection is unlikely to play a path-
ogenic role in ME/CFS, although an effect in initiating 
the disease process cannot be excluded [106].
Human parvovirus B19
B19V is an immunomodulating single-stranded DNA 
virus belonging to the Parvoviridae family, the Parvoviri-
nae subfamily, and the Erythrovirus genus. It was discov-
ered in 1975 in the serum of an apparently healthy donor 
[107].
B19V was first associated with a human disease in 1981 
[108]. It is frequently detected in children, and conse-
quently, 60–80% of adults have antibodies against this 
virus. It can cause rash, Erythema infectiosum or the fifth 
disease, arthralgia, various skin lesions, neutropenia, liver 
and lung disorders, papular-purpuric gloves and socks 
syndrome, hepato-biliary diseases, cardiac syndromes, 
autoimmune and neurological diseases, transient aplastic 
crisis with a short life-span and aplasia of red blood cells 
that is observed in immunocompromised patients [109, 
110]. Viral DNA is eliminated from the serum within 
4–5 months, and antibodies rapidly decrease. Many years 
after the primary infection and acute phase, B19V can 
persist in an organism, and persistent B19V infection has 
been investigated as a possible etiological agent in cases 
of encephalitis, encephalopathy, arthritis, autoimmune 
processes, fatigue and ME/CFS [111, 112].
Initial studies using PCR to examine the presence of 
B19V DNA in serum and bone marrow aspirates did not 
find evidence of involvement of B19V infection in bone 
marrow dysfunction in any of seven ME/CFS patients. 
Out of these 7 patients, only 1 patient had B19V specific 
antibodies [113]. Additionally, an analysis of 22 monozy-
gotic twins revealed the presence of B19V genomic 
sequences in only one of the healthy twins as detected by 
PCR [61].
A link between B19V infection and subsequent onset 
of ME/CFS (1–3 years post-infection) has been published 
[114]. The results from this analysis revealed a signifi-
cant association between the development of ME/CFS 
and high stress levels, as determined through the use 
of questionnaires, during acute B19V infection. Later, 
B19V DNA was found in plasma samples from 3/58 ME/
CFS patients and 2/49 healthy controls, while IgG class 
antibodies were observed in 52% and 57% of patients 
and controls, respectively, and IgM class antibodies not 
present at all [115]. Due to the detection of B19V DNA 
in gastro-intestinal biopsies from 40% of patients and 
fewer than 15% of controls, some researchers have con-
cluded that, at least in a subset of patients, B19V could be 
involved in the pathogenesis of ME/CFS [68].
While analysing the presence of B19V infection mark-
ers in the serum of 200 ME/CFS patients and 200 healthy 
blood donors using real-time PCR, B19V DNA was 
detected in 11 patients with ME/CFS but in none of the 
healthy blood donors. A significant difference was not 
revealed in B19V seroprevalence (the proportion of indi-
viduals with anti-B19 VP2 IgG class antibodies) between 
patients with ME/CFS, 75% of whom were seroposi-
tive, and donors, who had a total seroprevalence of 78%. 
Meanwhile, anti-B19V VP2 IgM class antibodies were 
found in 4 patients. In addition, 41.5% of patients and 
only 7% of donors had IgG class antibodies against non-
structural (NS1) protein, whereas B19V specific NS1 IgM 
class antibodies were found in 3 patients and one donor. 
The presence of B19V specific NS1 antibodies indicates 
a severe and persistent or chronic B19V infection; in this 
study, 73% of those with anti-NS1 antibodies suffered 
from joint pain, and positivity for these antibodies in 
ME/CFS patients was associated with greater expression 
of the human ME/CFS-associated genes NHLH1 and 
GABPA [116]. Another report described finding anti-
VP2 IgG class antibodies in 74% of the analysed patients 
with ME/CFS and IgM in 1 patient. As was the case in 
the aforementioned study by Kerr et al., B19V seropreva-
lence among ME/CFS patients was shown to be similar 
to the percentage in the general population [80]. More 
recently, B19V VP2 specific antibodies were detected in 
plasma samples from 85% of the ME/CFS patients and 
61% of practically healthy individuals [62]. Moreover, 
active B19V infection was detected in 28% of ME/CFS 
patients compared to 2% of controls using nested PCR, 
and active infection was linked to an increased frequency 
of joint pain [62]. In spite of these studies, there is no 
consensus on B19V as a causative agent of ME/CFS.
Retroviruses
Xenotropic murine leukemia related virus (XMRV) 
belongs to the Retroviridae family, Orthoretrovirinae sub-
family and Gammaretrovirus genus, which was identified 
in 2006 while studying the lack of ribonuclease L coding 
antiviral gene RNASEL function in patients with prostate 
cancer [117]. The genome has 95% homology with several 
endogenous murine retroviruses and 94% homology with 
exogenous murine retroviruses [10]. However, Paprotka 
et  al. concluded that XMRV is probably a recombinant 
virus, which was generated by the recombination of two 
murine retroviruses (pre-XMRV1 and pre-XMRV-2) 
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during passaging of prostate cancer cell lines in nude 
mice within a time period ranging from 1993 to 1996 
[118].
XMRV was discovered in patients with prostate cancer, 
and publications reported potential associations between 
the virus and other diseases. The observations of RNase 
L proteolysis in PBMC from patients with ME/CFS and 
infectious-like chronic immune system activation led to 
examination of XMRV in these patients [119, 120]. The 
XMRV gag gene sequence was detected by nested PCR 
in PBMCs of 67% out of 100 patients PBMCs but only 
in 3.7% out of 218 healthy donors PBMCs, and further 
analysis revealed 99% sequence identity with XMRV by 
sequencing viral genomes from 3 patients [120]. How-
ever, Science retracted this article in 2011, citing poor 
quality control in the experiments, the omission of 
important information regarding treatment of the ME/
CFS-patient PBMCs, and scepticism of the validity of the 
study [121].
In 2010, Lo et  al. reported on the detection of MLV-
related virus gag gene sequences in 86.5% out of 37 
patients and 6.8% out of 44 control group individuals 
[122]. However, in 2012, the authors retracted the publi-
cation. Later, many researchers published their efforts to 
detect XMRV in patients with ME/CFS and donors using 
serological and molecular methods. No evidence link-
ing XMRV to ME/CFS was found in studies carried out 
in Germany, China, Sweden, the United Kingdom, Japan, 
the United States of America, Canada, the Netherlands, 
Latvia and Italy [123–135]. The presence of XMRV or 
MLV-related sequences, antibodies, or infectious virus 
was not confirmed in large ME/CFS patient groups, 
including a subset of the patients previously reported to 
be XMRV-positive by Lombardi and colleagues [136].
It has been suggested that the earlier positive find-
ings were based on laboratory contamination [136–140]. 
Studies have shown that commercial reagents and clini-
cal samples could be contaminated with MLV-related 
virus genomic sequences containing murine DNA, and 
cloned or amplified XMRV DNA might be the source of 
contamination. It could also originate from frequently 
used XMRV-infected prostate cancer cell line 22Rv1 
[141]. Various geographic localizations may explain dif-
ferences in some results, but not in the same country. 
Another reason for problems with XMRV detection was 
thought to be XMRV sequence variation or the pres-
ence of XMRV-like viruses. XMRV strain identity is 99%; 
therefore, the existence of distinct or related viruses is 
possible, and detection of them with PCR or some other 
methods can be difficult [10]. After several years of stud-
ies, large effort and expenses from clinicians, scientists 
and patients, it was concluded that there is no association 
between XMRV and human diseases, and positive results 
were consequences of contamination [142].
Studies on several other retroviruses (HTLV-I and -II, 
HIV-1/2, spuma viruses) in ME/CFS were performed. 
Whereas DeFreitas reported on the presence of antibod-
ies to HTLV-II and retroviral sequences in blood cells 
in patients with ME/CFS, these findings could not be 
reproduced by other groups [76, 143, 144]. Therefore, the 
theory of retroviral etiology in ME/CFS is not currently 
supported.
Ross River virus
Another post-viral fatigue-causing virus is a single-
stranded positive-sense RNA virus—Ross River virus 
(RRV), which belongs to the family Togaviridae, genus 
Alphavirus. Mosquitoes transmit this viral infection 
from infected animals to humans, and symptoms of the 
infection overlap with the symptoms of ME/CFS. Back 
in 1996, Selden and Cameron published a study in which 
such symptoms as joint pain, persistent tiredness, leth-
argy, myalgia, lymphadenopathy, headache, and depres-
sion were observed even 30 months after infection with 
RRV in South Australia [145].
Using an antibody-dependent enhancement mecha-
nism, RRV has been found to infect macrophages and 
enable suppression of specific antiviral genes expressed 
by these cells, which results in unimpeded replication 
[146]. An additional study by these two authors showed 
suppression of functional activity of STAT1 and NF-κB 
transcription factor protein complexes due to antibody-
dependent enhancement of RRV infection [147].
Later, acute RRV or EBV infection followed by fever, 
malaise, pain, fatigue, and mood and concentration dis-
orders were correlated with elevated levels of pro-inflam-
matory cytokines [148]. Analysing the same patient 
cohort in Australia, Hickie and colleagues studied the 
prevalence and course of post-infectious fatigue and 
chronic fatigue following acute RRV, EBV and Coxiella 
burnetii infection, demonstrating that severity of acute 
viral infection and the host response to it may determine 
the course of post-infectious syndrome and ME/CFS [82]. 
More recent attempts to find a possible illness-specific 
signature of peripheral blood gene expression in patients 
with post-infectious fatigue caused by RRV, EBV, or Cox-
iella burnetii, was not successful [149]. Subsequently, this 
team hypothesized that inflammatory cytokines influ-
ence the CNS, resulting in neurocognitive disturbances 
following acute infection, and therefore, certain infec-
tious agent may not determine symptoms. Moreover, 
genetic predisposition of specific cytokine expression has 
been found to affect cognitive manifestations, particu-
larly during acute infection [150].
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Molecular mechanisms behind viral pathogenesis 
in ME/CFS
Viral infection can initiate a multitude of physiologi-
cal changes in host cells that can contribute to ME/
CFS development (Fig.  1). Viral pathogens frequently 
associated with ME/CFS are also known to alter various 
molecular processes in host cells that define clinical 
conditions of ME/CFS (Table 3). Three of the most fre-
quently discussed molecular processes, namely immune 
cell alterations, mitochondrial modulation and autoim-
munity, are described in brief within this section.
ME/CFS

















Activation of autoreactive 
immune cells








Ross River virusParvovirus B19
Fig. 1 Schematic diagram showing various viral pathogens potentially associated with ME/CFS and possible molecular mechanisms altered by 
these pathogens that can contribute to ME/CFS development
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Virus‑induced alterations to immune cells
One commonality among the viruses linked to ME/
CFS appears to be the ability to establish persistent 
infections. In order to do that, viruses must bypass and 
evade immune cells, and in doing so may alter immune 
cell functions. While several viruses may contribute 
to ME/CFS, the immunomodulatory capacity of the 
viral species, perhaps paired with its ability to estab-
lish persistent infection, may underlie its pathological 
potential in the setting of ME/CFS. Elevated activity 
of antiviral enzyme 2′-5′-oligoadenylate synthetase 
(OAS) in PBMC from patients with ME/CFS has been 
observed. This protein is induced by IFN-α and IFN-β, 
and degrades viral RNA and inhibits virus replication. 
Therefore, it plays an important role in the response 
against viral infections. The level of OAS correlates with 
severity of ME/CFS, suggesting that a chronic virus 
infection could be the cause of ME/CFS [151]. Moreo-
ver, proof of humoral immune response activation by 
herpesviruses-encoded dUTPases in patients with ME/
CFS has been published [85].
The establishment of a persistent infection is influenced 
by immunosuppression and activated immune com-
plexes, which may cause chronic inflammation [15, 152, 
153]. Chronic immune system activation is accompa-
nied by alterations in regulation of cytokine production 
[154], and stimulated lymphoid cells express or induce 
the expression of various cytokines in other cells that 
can set the stage for pathological manifestations [155]. 
Low-level inflammation and activation of cell-mediated 
immunity is observed in ME/CFS cases and the high 
level of TNF-α correlates with several clinical symptoms; 
therefore, an increase of inflammatory mediators might 
explain symptoms of the disease [156]. Likewise, it is pos-
sible that a viral infection causes dysfunction in cellular 
immunity, which consequently induces viral reactivation. 
Subsequently, viral proteins facilitate cytokine secretion, 
resulting in appearance of typical ME/CFS symptoms, 
Table 3 Possible viral contributions towards ME/CFS
Viruses Contribution in ME/CFS
Human herpesviruses Persist after primary infection in latent phase and can reactivate causing lytic virus replication
Infected cells are recognized by immune system resulting in chronic inflammation that causes ME/CFS symptoms
Disturb first class major histocompatibility complex (MHC) molecules presenting virus antigen
Alter NK, T and B cell function
Modify expression of cellular transcripts
Trigger immune dysregulation
Alter cytokine production resulting in appearance of ME/CFS typical symptoms
Contribute in affecting signalling pathways to proper immune response
Activate humoral immune response by herpesviruses‑encoded dUTPases
Infect neurons and immune cells to impair CNS capillaries and micro‑arteries, leading to brain damage
Produce a pro‑inflammatory environment and autoimmune activity
Damage tissue, leads to inflammation and may activate auto‑reactive T and B cells, thereby contributing to autoimmunity
Local virus‑associated inflammation of nervous structures results in altered CNS and PNS signalling
Alter ATP homeostasis, increase ROS, change mitochondrial metabolism and modulate mitochondrial DNA content
Enteroviruses Infect various tissue (blood, gastric, muscle, brain) and stool
Persistence of viral RNA could contribute to muscle dysfunction
Induce tissue damage
Dysregulate host microRNAs
Induce greater oxidative stress, inflammation, and pro‑inflammatory M1 macrophage activity
Induced inflammation can result in bystander activation of auto‑reactive cells
Coxsackie B4 virus infects beta cells leading to NK cell induced non‑destructive inflammation
Severe acute enterovirus 71 infection diminishes number of NK and T cells and induces ROS accumulation
Parvovirus B19 After primary infection and acute phase can establish persistent infection and lead to the manifestation of ME/CFS
Interacts directly with cells leading to a more aggressive fibroblast function and degradation of cartilage matrix
Active infection is linked to an increased frequency of joint pain
VP1 protein affects arachidonic acid metabolism promoting inflammatory reactions
NS1 protein stimulates pro‑inflammatory cytokines production causing local inflammation
Activates NK cells
Causes neuroinflammation
Contributes to greater expression of the human CFS‑associated genes NHLH1 and GABPA
May induce autoimmunity
Retroviruses No contribution
Ross‑River virus Infect macrophages using antibody‑dependent enhancement mechanism
Suppresses transcription and translation of antiviral genes
Generate neurocognitive manifestations affected by functional polymorphisms in cytokine genes
Cause joint pain, persistent tiredness, lethargy, myalgia, lymphadenopathy, headache and depression
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such as fatigue, fever, sleep and cognitive disorders [7]. 
Chronic pain may be caused by inflammatory signals 
that are spread by glial cells activated by inflammatory 
cytokines and neuronal stimulation [153, 157].
In establishing persistence, viruses may induce immune 
disturbances directly and indirectly; for instance, they 
may infect cells involved in mediation of cellular and 
humoral immune response, and through indirect interac-
tions, they might alter cell surface receptor expression as 
well as cytokine and chemokine expression levels, leading 
to local inflammation [158]. Infection of cells by entero-
viruses affects cellular miRNA expression, which may 
result in dysregulation of immune pathways and cytokine 
production, and these viruses can reduce expression of 
type I and III interferon, which are primarily produced by 
natural killer (NK) and T cells [159–161]. Herpesviruses 
like HHV-6 are also able to alter expression of cellular 
miRNAs in various cell types including NK cells [162, 
163], as well as cellular expression of NK cell receptors 
[164], and they may express their own miRNAs that aid 
in immune evasion [165]. Downregulated cytotoxic activ-
ity of NK cells in ME/CFS could be linked to a decreased 
expression level of NK cell activating receptor NKG2D 
[166], the ligand of which is down-regulated by HHV-
6B [164]. In addition, the expression of viral homologs of 
cytokines/chemokines and cytokine/chemokine recep-
tors by herpesviruses can impact immune pathways [167, 
168]. Other herpesvirus-induced alterations to ligand/
receptor signalling between NK and associated cells 
could also contribute to the pathogenic mechanism of 
the viruses in ME/CFS are described [169].
Enteroviruses, as well as most of the herpesviruses, use 
mechanisms that disturb first class major histocompati-
bility complex (MHC) molecules presenting virus antigen 
[167, 170, 171]. The HHV-7 U21 gene product interrupts 
viral antigen presentation to cytotoxic T cells that causes 
MHC class I molecules degradation in lysosomes. Besides 
interfering with the host cytotoxic T cell response, 
U21 lessens NK cell cytotoxicity [172]. Such changes of 
immunological parameters as a decreased count of  CD3+ 
and  CD4+ T cells, an increase of  CD95+ and a decrease 
of  CD4+/CD8+ ratio are observed in patients with a con-
current active HHV-6 and HHV-7 infection [64]. Other 
studies also show  CD4+ T cell response to HHV-6 [173].
In vitro studies show that a possible mechanism of 
action for B19V is direct virus interaction with cells 
leading to more aggressive fibroblast functionality and 
degradation of cartilage matrix. Moreover, the activity 
of capsid protein VP1 affects arachidonic acid metabo-
lism promoting inflammatory reactions, and the B19V 
non-structural NS1 protein also stimulates pro-inflam-
matory cytokine production, causing local inflamma-
tion [174] that might account for such ME/CFS clinical 
manifestations as fatigue, lymphadenopathy, joint pain, 
and muscle pain [68, 175, 176]. Enteroviruses [177, 178] 
and herpesviruses may also contribute to these signs and 
symptoms through up-regulation of pro-inflammatory 
cytokines [179].
Some viruses, like RRV, are able to infect macrophages 
using an antibody-dependent enhancement mechanism, 
suppressing antiviral genes and thereby resulting in repli-
cation [146]. The antiviral response to RRV is diminished 
by suppression of transcription factor protein complex 
activity [147]. In the case of acute RRV infection, func-
tional polymorphisms in cytokine genes may affect the 
influence of inflammatory cytokines in the CNS and 
resulting neurocognitive manifestations [150].
Viruses and mitochondrial modulation
ME/CFS is considered to be a mitochondrial disease 
[180]. Some of the characteristic features of ME/CFS 
involve altered adenosine triphosphate (ATP) homeosta-
sis [181, 182], increased reactive oxygen species (ROS) 
[183], changed mitochondrial metabolism [184, 185], and 
modulation of mitochondrial DNA content [182, 186, 
187]. Many of the aforementioned viruses modulate host 
mitochondria in a variety of ways that can potentially 
present plausible explanations regarding the involvement 
of these viruses in ME/CFS. Viruses have evolved distinc-
tive strategies to alter mitochondrial metabolism and 
bioenergetics, which may allow enhanced viral replica-
tion and provide anti-viral defence.
HSV-1 infection decreases cellular ATP levels and 
mitochondrial membrane potential [188], and HSV-1 
anti-apoptotic protein gJ has been shown to induce ROS 
formation [189]. In vitro experiments in mammalian cells 
have shown rapid and complete degradation of host mito-
chondrial DNA by HSV-1 [190]. Evidence of mitochon-
drial dysfunction has been associated with post-infective 
fatigue after EBV infection [191], and EBV is known to 
alter mitochondrial dynamics through direct interaction 
[192]; the immediate early protein of EBV, Zta, interacts 
with mitochondrial single stranded DNA binding pro-
tein, leading to reduced mitochondrial DNA (mtDNA) 
replication and enhanced viral DNA replication [193]. 
HHV-6B improves viral infection through direct inter-
action of its U95 protein with human GRIM-19 protein 
[194], and the virus increases oxidative stress during 
persistent infection by reducing glutathione reductase 
activity [195]. During productive infection, HHV-6A 
can cause apoptosis through a caspase-dependent path-
way accompanied by altered mitochondrial morphology 
and lower transmembrane potential [163, 196]. Similarly, 
latent CMV has been associated with greater oxidative 
damage [197]. HHV-8 modulates mitochondrial antivi-
ral signalling via its interferon regulatory factor 1 [198]. 
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In addition, porcine and canine parvovirus infection 
induces depolarization of the mitochondrial membrane, 
damage to the organelle’s structure [199], and ROS accu-
mulation [200, 201]. Enterovirus 71 also induces ROS 
accumulation [202] for its successful replication.
Viruses and autoimmune signature
Autoimmune signature in ME/CFS has recently become 
a subject of intense research [29, 203]. Viral pathogens 
can contribute to autoimmune diseases in variety of 
ways. Because the viruses associated with ME/CFS are 
also commonly detected among healthy individuals, it 
may be the case that underlying immune dysfunction 
in the host acts as a predisposing factor in development 
of the disorder. Viruses may trigger immune dysregula-
tion, but an individual may also be predisposed to either 
an exceptionally strong acute infection, an inability to 
completely clear the virus, or both. Subsequently, the 
abnormal immune profile post-acute infection may allow 
for continuous reactivation and incomplete clearance of 
pathogens, resulting in tissue damage and an overactive 
yet ineffective immune response leading to inflammation 
and autoimmune changes. The absence of strong viremia 
indicates that the viruses that are present are likely quite 
tissue-specific, and data suggests that the viral activ-
ity consists of greater “latency-associated replication”, 
as was noted for EBV [72]. The success of valganciclovir 
(active against CMV and HHV-6) and valacyclovir (active 
against HSV, VZV, and EBV) [86, 204] as well as rituxi-
mab and immunoadsorption of ß2 autoantibodies in 
subsets of ME/CFS patients suggests that both the viral 
activity itself and the immune response against/result-
ing from viral infection may contribute to the signs and 
symptoms of the illness [205, 206].
Enteroviruses, particularly B coxsackieviruses, are 
implicated in type 1 diabetes mellitus, which they may 
contribute to through dysregulation of host microRNAs 
[207] and induction of greater oxidative stress, inflam-
mation, and proinflammatory M1 macrophage activ-
ity [208]. Chronic enterovirus-associated systemic or 
local inflammation, as a consequence of a weak innate 
immune response and virus-induced tissue damage, 
may result in bystander activation of auto-reactive cells. 
On the other end of the spectrum, an overactive innate 
immune response may also result in inflammation during 
the initial acute infection, leading to the same outcome 
[209]. This scenario has been proposed for enteroviruses 
in type 1 diabetes, but the theory may be more broadly 
applicable to other viruses and autoimmune conditions. 
Activation of auto-reactive bystander cells has also been 
proposed as a pathogenic factor in systemic lupus erythe-
matosus [210], as has molecular mimicry.
The viruses discussed herein are capable of activating 
NK, B, and T cells, modifying expression of their cellu-
lar transcripts, altering cytokine production, and affect-
ing signalling pathways integral to the proper functioning 
of the immune response, potentially producing a pro-
inflammatory environment and autoimmune activity. 
For example, NK cells induce non-destructive inflam-
mation in response to beta cell infection by coxsackie B4 
enterovirus [211] and are activated by acute B19V infec-
tion [212], but NK and T cells are diminished in number 
during severe acute infection of enterovirus 71 [213]. 
HHV-6A-infected T cells express many miRNAs asso-
ciated with inflammation and autoimmunity [214], and 
persistent HHV-6A infection is associated with altered 
NK cell profiles in cases of Hashimoto’s thyroiditis and 
acute necrotizing encephalopathy. These infections were 
characterized by incomplete clearance of the virus and 
a greater abundance of peripheral CD56bright NK cells 
[215, 216]. This environment of heightened cytokine 
secretion paired with the ineffectual clearance of infec-
tion may activate auto-reactive T and B cells, thereby 
contributing to autoimmunity. Indeed, the cellular activa-
tion of the CD56bright NK cells correlated with autoanti-
body levels in subjects with Hashimoto’s thyroiditis.
Interactions between the viruses and innate and adap-
tive immune cells are dynamic and vary temporally, 
across viral species, and between individual patients. 
Accordingly, activity of these cells has been found to 
vary across studies of ME/CFS and even within studies, 
according to the time-point [217]. Although cytokine 
expression and immune cell phenotypes have differed 
[62, 218], dysregulation of immune cell networks occurs 
in ME/CFS patients, and a pro-inflammatory milieu 
appears to predominate. Additionally, it is clear that 
patients’ immune responses against viruses differ from 
unaffected individuals. While healthy volunteers did not 
exhibit changes in cellular proliferation after vaccination 
with influenza strains, for example, ME/CFS patients 
displayed significantly higher cellular proliferation in 
response to stimulation compared to baseline [219]. 
Baseline T cell proliferation was lower than controls, 
and post-vaccination proliferation was higher in ME/
CFS patients compared to controls, although these find-
ings were not statistically significant. Lower proliferative 
responses were observed among other ME/CFS patients 
as well [220], and decreased cytotoxicity of NK and T 
cells [217], as well as increased levels of cytokine produc-
ing CD56bright NK cells [221], have been documented, 
although findings have not been consistently confirmed 
between studies.
Failure to produce IgG antibodies against EBV EBNA-1 
has been noted, as has low levels of antibody secret-
ing cells specific to EBNA-1 and VCA and an impaired 
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B cell memory response to the virus [72]. Responses of 
EBV-specific B- and T-cells were suppressed, which has 
been suggested to result from frequently reactivated EBV 
and lymphocytic exhaustion. In contrast, reduced CMV 
and HSV specific B-cell responses were not identified. 
On the other hand, the presence of antibodies against 
EBV DNA polymerase and EBV-encoded dUTPase 
has been detected in the serum of a subset of ME/CFS 
patients but not in controls [84], and the IgG response to 
EBV EBNA-6 peptides has been heightened in ME/CFS 
[73]. Sequences of amino acids in the EBNA-6 repeat 
region were found to be homologous to the human lac-
toperoxidase precursor (LPO) and thyroid peroxidase 
precursor (TPO) proteins as well as the two enzymes 
ornithine transcarbamylase (OTC) and phosphofruc-
tokinase-1 (PFK-1), which have metabolic functions. 
Of these, only LPO peptide IgG levels correlated with 
EBNA-6 peptide and protein IgG. However, antigenic 
mimicry producing cross-reactivity among these proteins 
is considered as a possible factor behind ME/CFS patho-
genesis. Analysis of genetic associations has revealed that 
the EBV protein EBNA-2 and its related human tran-
scription factors are associated with many autoimmune 
risk loci, including those involved in MS, rheumatoid 
arthritis, type 1 diabetes, and systemic lupus erythemato-
sus [222]. NF-kB was similarly associated.
Although systemic immune dysfunction has been 
observed, local virus-associated inflammation of nerv-
ous structures resulting in altered CNS and peripheral 
nervous system signalling has also been hypothesized 
as a mechanism behind ME/CFS [223, 224], and neuro-
inflammation has been observed in patients [225]. EBV 
[226], HSV [227], HHV-6 [228], CMV [229], VZV [230], 
enterovirus [231], and B19V [232] can all infect the brain. 
Notably, HHV-6A is able to induce neuroinflammation in 
the absence of active replication in a mouse model [233]. 
HHV-6A has also been found to impair myelin repair 
in  vitro and in  vivo using mouse with extensive loss of 
myelin [234].
HHV-6 has been strongly linked to autoimmune dis-
eases like Hasimoto’s thyroiditis [235, 236], connective 
tissue disorders and MS [237]. Selective reactivation of 
HHV-6 has also been shown in patients with autoim-
mune connective tissue diseases [238]. MS patients are 
frequently detected with high levels of HHV-6A/B-spe-
cific IgG and IgM in the serum and CSF [239]. Myelin 
basic protein (MBP), one of the auto-antigens impli-
cated in MS pathology shares amino acid sequence 
homology with the U24 protein from HHV-6 [240]. 
Hence molecular mimicry is considered as one of the 
potential mechanisms for HHV-6 mediated autoim-
mune diseases. Clinical cases showing increased glu-
tamic acid decarboxylase (GAD) antibodies and HHV-6 
infection has been reported where antiviral therapy 
improved patient’s clinical condition [241].
HHV-6B has weaker ties to autoimmunity, but it is 
thought to contribute to common symptoms of severe 
drug-induced hypersensitivity syndrome/drug reac-
tion with eosinophilia and systemic symptoms (DIHS/
DRESS) when it reactivates strongly during the course 
of the syndrome. The immune response to the viral 
activity is considered as potentially more destructive 
than the viral activity itself and is implicated in visceral 
organ damage [242]. Notably, initial regulatory T cell 
(Treg) expansion in this illness contrasts with subse-
quent exhaustion of Treg cells during remission, which 
appears to set the stage for the autoimmune sequelae 
that commonly occur afterward [243]. Autoimmune 
thyroiditis and diabetes mellitus frequently arise post-
DIHS/DRESS, as does chronic fatigue. HHV-6 has 
been detected in Treg cells in a case of likely DIHS/
DRESS [244], and HHV-6A [245] and HHV-6B [246] 
are also able to induce the development of Treg cells. 
Both upregulated and reduced levels of Tregs have been 
reported in ME/CFS [217, 221, 247].
The molecular link between B19V infection and auto-
immune disorders is not very clear. However, B19V 
infection has been associated with development of auto-
immune antibodies including rheumatoid factor [110, 
248, 249], antinuclear antibody, anti-mitochondrial anti-
body, smooth muscle antibody, and gastric parietal cell 
antibody [250]. Recently, B19V infection has been shown 
to increase levels of cytokines like IL-4, IL-10, IL-12, IL-2 
and TNFα in the plasma of rheumatoid arthritis patients 
[251]. B19V induced upregulation of IL-6 has also been 
noted for its potential role in autoimmunity [252]. Two 
of the B19V proteins, a proline-rich small protein [253] 
and the NS1 protein [254], which also function as a tran-
scription regulator have been intensely studied because 
of their role in viral pathogenesis. These proteins also 
contribute to host cell immune modulation through their 
involvement in cell survival pathways [254, 255]. B19V 
has been implicated in clinical cases of systemic lupus 
erythematosus and rheumatoid arthritis where various 
auto-antibodies could be detected in patients. Intra-
venous immunoglobulin (IVIG) has been reported to 
reduce symptoms in some patients with persistent B19V 
infection, but IVIG administration has also resulted in 
unexpected worsening of symptoms in a ME/CFS patient 
[256]. This may indicate that, in some cases, the immune 
response against persistent infection contributes to the 
development of clinical symptoms more so than infec-
tion-induced tissue damage, and IVIG may contribute to 
increased inflammation. Heightened viral replication was 
also detected in this case, which was suggested to be a 
result of antibody-dependent enhancement.
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At least in a subset of patients, the mitochondrial dys-
function and elements of autoimmunity that character-
ize ME/CFS may be linked to viral pathogenesis. Lack of 
extensive analysis of molecular mechanisms linking viral 
pathogens to ME/CFS restricts our understanding of this 
disease. Future studies need to focus on this aspect of 
ME/CFS research.
Conclusions
Currently available data on the role of chronic viral infec-
tion with ME/CFS is still controversial, showing poten-
tial viral involvement for at least a subgroup of ME/CFS 
patients. Therefore, it is necessary to assess the presence 
and markers of viral activity at the initial stage of the dis-
ease to evaluate possible etiological factors and conduct 
longitudinal studies in order to assess active viral infec-
tion and symptom severity variations over time. Moreo-
ver, results should be compared not only between ME/
CFS patients and controls, but also with other co-mor-
bidities to assess specificity of suggested biomarkers.
Considering ME/CFS heterogeneity, the use of clini-
cal characteristics  and biomarkers to enable definition 
of the disease subtypes is crucial. In addition, longitu-
dinal and standardized studies determining ME/CFS 
course and therapy effectiveness with follow-up meas-
urements in dynamics should be accomplished. This will 
allow prognosis of the disease development and promote 
development of a specific definition for diagnostics and a 
treatment plan.
Future strategies for development of infection 
biomarkers in ME/CFS
1. Use of quantitative assays rather than qualitative 
assays to assess the extent of the viral load instead 
of simple detection of presence or absence. This may 
facilitate monitoring of a response to treatment; 
however, diurnal variations and individual response 
on treatment should be taken into account. Further 
comprehensive serological testing may help to iden-
tify a signature of active infection.
2. Use of additional biological samples together with 
blood and serum will be useful in determining the 
localization and distribution of biomarkers, as well 
as pathogenicity. Using hair follicles, virus integration 
can be detected. Similarly throat swab and stool sam-
ples can be used for detection of enteroviruses.
3. Functional studies to compliment clinical biomarker 
studies in order to clarify functions and interactions 
of genes, transcripts, proteins, and immune cells 
and molecules in cases of ME/CFS. This will facili-
tate understanding of the disease aetiology as well 
as development and maintenance pathways, and 
thereby, potential prevention and treatment strate-
gies. However, this strategy requires definition of 
ME/CFS subgroups.
4. Use of high throughput methods to gain broader 
insight into potential biomarkers for infections by 
obtaining and analysing large-scale data, which will 
raise the quality and significance of the research.
5. Confirmation of results by validation studies and 
multi-centre cohort studies to obtain generalizability 
of the study and promote implementation of credible 
biomarkers usable worldwide.
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